Market Access 2020: Understanding US Payer Expectations
How Much Longer For Biopharma’s Habitual Hamlet Fixation: To Risk Or Not To Risk?
Executive Summary
Big pharma is facing a difficult US competitive landscape as its traditional customers realign to build their own redoubts of size, scale and reach.